Therapeutic drug monitoring of digoxin and its management by Marshall, Keith A.
THERAPEUTIC DRUG MONITORING OF 
DIGOXIN AND ITS MANAGEMENT 
Marshall Keith A. 
Introduction 
Digoxin, together with diuretics, constitutes the traditional approach to 
the treatment of congestive heart failure. However, several serious 
doubts have been cast in relation to the use of the drug, due to its narrow 
therapeutic range. Monitoring digoxin blood levels should enable the 
clinician to tailor the dose and produce a therapeutically-valid blood 
concentration. However, questions could be raised regarding how much 
information can be derived from serum digoxin concentrations which 
cannot be inferred from clinical observation alone. 
Studies were carried out: 
1) to assess and verify the physician's reasons for 
requesting serum digoxin levels 
2) to investigate digoxin dosage regimens and routes of 
administration employed in a local health centre 
3) to investigate inter- and intravariability in serum digoxin levels 
for a population of geriatric patients 
4) to assess the predictive powers of a computerised system in 
determining serum digoxin levels 
Methodology 
Study 1: A questionnaire was issued to all house physicians, 149 in 
number, at St. Luke's Hospital. This consisted of a list of generally 
accepted indications for requesting serum digoxin concentrations. The 
physicians were asked to indicate those reasons which they considered 
valid. 
Study 2: This study investigated the dosage regimens and routes of 
administration adopted for digoxin at Saint Vincent de Paule Residence 
(SVPR). All the 57 patients taking digoxin at the residence were 
considereq. Relevant information was obtained from the patients' 
medical histories and through questioning of the hospital staff. 
Study 3: The degree and extent of intervariability and intravariability 
in serum digoxin levels in a population of digitalised patients at SVPR 
was assessed. Information was obtained from the patients' medical 
histories. 
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a) The patients were grouped according to the current daily dose 
being administered, and the corresponding serum level taken, 
classified as sub-therapeutic, therapeutic or toxic. 52 patients out 
of the 57 in Study 2 were eligible for the intervariability study. 
Of the 5 patients considered ineligible 3 were being administered 
exceptional doses (2 on O.1875mg daily, 1 on 0.125mg twice daily), 
whilst the other 2 patients died, and had to be omitted, since a 
serum digoxin had not been taken at that particular dosage 
strength. Of the remaining 52 participants, 14 had not had a 
serum digoxin level taken at the then current dose of digoxin on 
which day were being maintained. It was therefore, necessary to 
request the taking of such blood levels (these being carried out at 
the Pathology Department, St. Luke's Hospital,through RIA). Of 
the 14 requests submitted, 11 were taken, the results of which 
were included in the study, whilst 3 patients were non-compliant, 
and would not allow a blood sample to be taken for analysis. 
b) To be eligible for the intravariability study, patients had to 
have at least 3 serum digoxin levels taken when on a particular 
dosage regimen. 21 patients out of the 57 in Study 2 were eligible. 
The serum digoxin levels for each patient were classified as sub-
therapeutic, therapeutic or toxic. 
Study 4: In this study, patients who (i) rad undergone a change in dosage 
regimen and (ij) had their serum digoxin levels measured when on both 
regimens were considered. The patients' data were keyed into a 
computerised system for dosing and therapeutic drug monitoring 
(SIMKIN), and thc predicted serum digoxin levels obtoined were 
compared with the actual ones (i) for the first level taken and (ii) for 
the second level, after the system had modified the patient's volume of 
distribution and elimination half-life according to the first serum level. 
Results 
Of the 149 questionnaires issued, 56 were returned completed, 16 were 
returned unanswered and 77 physicians failed to answer. 
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Table 1: Classification of physicians' reasons for requesting serum 
digoxin levels 
Reason Number of physicians 
Routine check 
Suspected underdigitalization 
Suspected overdigitaliza tion 
Suspected clinical toxicity 
Lack of history on digoxin use 
Unexpected degree of response to a dose 
Patient on unusually large or small dose 
Suspected non-compliance 
Suspected bioavailability problems 
Suspected drug interactions 
Suspected pharmacokinetic interference 
from concurrent disease 
Others 
Study 2 
No. % 
10 
22 
56 
6 
52 
16 
48 
10 
12 
30 
1 
o 
17.8 
39.0 
100.0 
10.7 
93.0 
28.6 
85.7 
17.9 
21.4 
53.6 
0.0 
0.0 
Table 2: Classification of dosage regimens and routes of administration 
at SVPR 
Dosage Daily dose Frequency Number of patients 
form (mg/day) of dosing No. % 
Tablet 0.0625 once daily 9 15.8 
Tablet 0.125 once daily 33 57.9 
Tablet 0.1875 once daily 2 3.5 
Tablet 0.25 once daily 12 21.1 
Tablet 0.25 0.125 bd 1 1.8 
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Table 3: Classification of intervariability of serum digoxin levels in 
patients on various dosage regimens 
Dosage No. of Serum Digoxin Levels 
Regimen patients sub- Therapeutic Toxic 
(mg/day) on regimen therapeutic 
0.0625 9 6 3 
0.125 31 10 17 2 
0.250 12 9 2 
Table 4: Classification of intra variability of serum digoxin levels in 11 
patients on various dosage regimens 
Dosage No. of Serum Digoxin Levels 
Regimen patients sub- Therapeutic Toxic 
(mg/day) on regimen therapeutic 
0.0625 10 6 4 
0.0625 4 3 1 
0.125 6 2 4 
0.125 4 3 1 
0.125 3 2 1 
0.125 3 2 1 
0.125 3 1 2 
0.125 4 3 1 
0.125 4 3 1 
0.25 3 2 1 
0.25 3 2 1 
Srudy4 
When SIMKIN was run using the data collected from SVPR, it was found 
that for the first serum digoxin level, the actual and predicted levels 
were statistically different according to the student's t-test 
(tcalculated=2.086, ttabulated=2.056, p>0.05 n=27). However, after the 
patient's data was adjusted by the program on the basis of the first level, 
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the actual and predicted levels for the second serum digoxin similar were 
statistically similar (tcalculated =0.0786, ttabula ted =2.086, p>0.05 
n=27). Moreover, the % changes in tl/2 and V d needed to optimize the 
program to the patient were found to be greater after the first digoxin 
level was keyed in than after the second level was input. 
Table 5: Table showing statistical difference in mean % changes in V d 
and t1 /2 needed to optimize program to patient after first and second 
digoxin levels (n=27, p>0.05, ttabulated=2.056) 
Parameter 
Vd 
tl/2 
Conclusion 
Point 1 
+32.76% 
-10.60% 
Point 2 
+0.159% 
+1.730% 
tcalcula ted 
4.246 
2.581 
The reasons listed in the questionnaire have all previously been 
identified as important reasons, for requesting serum digoxin levels. 
Hence, the ideal answer to this questionnaire would have been to 
indicate all the reasons. In actual fact, only 1 physician did so. The most 
notable reason which was not indicated as acceptable by local physicians 
was 'Suspected pharmacokinetic interference from concurrent disease'. 
This is in fact so important that renal function is routinely checked when 
a patient is on digoxin therapy. 
All of the patients at SVPR were given oral therapy. 15.8% of patients 
were on a 0.125mg daily dosage. Since this dosage strength was not 
available, it was observed that it was considered preferable by hospital 
staff to administer half a 0.25mg tablet, rather than adopting the more 
accurate method of giving the patient two tablets of 0.0625mg. similarly, 
the 0.1875mg dose was administered by giving 3/4 of a 0.25mg tablet, 
rather than 3 0.0625mg tablets. Such a practice leads to a large degree of 
inaccuracy, and hence a loss of therapeutic efficacy. 
The ultimate goal in drug therapy is to administer an appropriate dose of 
a drug, such that the serum levels subsequently fall within the 
therapeutic range, resulting in therapeutic efficacy. This also minimises 
adverse effects. Such a practice is not simple with digoxin, due to the 
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narrow therapeutic range (0.8 - 2.1ng/ml). This is attested to by the 
inter- and intra variability observed in serum digoxin levels. Such a fact 
accentuates the need for therapeutic drug monitoring of digoxin. 
Computerised aids for therapeutic drug monitoring are becoming 
increasingly more effective, as the study with the SIMKIN program 
revealed. It was in fact shown that without a blood sample, the program 
can adequately predict expected serum concentrations though not with 
notable accuracy. However, following the keying in of a single blood 
level, and subsequently refining the patient's pharmacokinetic 
parameters, the program could accurately predict subsequent blood 
concentrations. The regular use of such a computerised pharinacokinetic 
aid would therefore greatly help in increasing the degree of therapeutic 
efficacy obtained when prescribing with digoxin. 
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